As ADC approvals grow and pipelines expand, dose selection has become one of the field’s biggest challenges, and Project Optimus has resulted in pushing developers to move beyond maximum tolerated dose and define regimens that truly balance safety and efficacy.

Increasingly complex ADC design only amplifies these challenges; bispecifics, dual payloads, and combination regimens are all contributing to increased scrutiny and effect on PKPD profiles and clinical pharmacology.

The 2nd ADC Pharmacokinetics & Clinical Pharmacology Summit brings together experts in PKPD, bioanalysis, pharmacometrics, and clinical pharmacology to share novel data and real-world case studies. Collaborate with 40+ colleagues across biotech, pharma, and academia in a focused environment to exchange knowledge, refine dose strategies, and accelerate the delivery of safe, effective ADCs to patients.

View the event here.